Compare Amylx Pharmaceuticals Inc (AMLX) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Nasdaq Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Nasdaq Inc trades at $88.08 (market cap $49.81B). The key difference: Nasdaq Inc is far larger — about 25.2× Amylx Pharmaceuticals Inc's market cap, and Nasdaq Inc pays a 1.27% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | NDAQ | |
|---|---|---|
Market Cap | $1.98B | $49.81B |
Sector | Health | Financials |
52-Week High | $18.70 | $100.98 |
52-Week Low | $7.64 | $76.85 |
Enterprise Value | $1.70B | $56.88B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Nasdaq (NDAQ) trades at $88.08, up 0.64% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. Revenue grew to $8.26 billion in 2025, with net income margin expanding to 23.03%. The stock shows robust institutional support, with 61% of analysts rating it a Buy and a consensus price target of $105.60, indicating ~20% upside potential.
Outlook remains positive given Nasdaq's dominant market position and exposure to capital markets growth, though risks include high valuation multiples (P/E 26.53) and sensitivity to equity market volatility. The stock's recent strength near resistance at $89 may prompt consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
